Global Primary Hyperoxaluria - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035

Global Primary Hyperoxaluria Market Outlook

Thelansis's "Global Primary Hyperoxaluria Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Hyperoxaluria treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Primary Hyperoxaluria Overview

Primary hyperoxaluria is a rare inherited metabolic disorder, most commonly type 1, in which a defective liver enzyme causes excessive oxalate production. This leads to recurrent kidney stones, progressive calcium oxalate deposition, declining kidney function, and, in advanced disease, systemic oxalosis affecting multiple organs. Historically, patients with kidney failure often required combined liver-kidney transplantation because replacing the liver was the only way to correct the underlying metabolic defect. The introduction of RNA interference therapies has transformed care by reducing hepatic oxalate production without transplantation, marking one of the clearest examples of gene-silencing technology entering routine clinical practice, including in children. Lumasiran and nedosiran target different enzymes in the oxalate production pathway, although their approved indications vary by disease subtype and regulatory region.

Key Highlights

• In Germany, diagnosed Primary Hyperoxaluria (PH) cases are projected to increase from 168 in 2025 to 171 by 2035.
• Primary Hyperoxaluria is a rare inherited metabolic disorder characterized by excessive oxalate production, leading to recurrent kidney stones and progressive renal damage.
• Delayed diagnosis can result in irreversible kidney dysfunction and systemic complications.
• Significant unmet need remains for therapies that prevent disease progression and preserve kidney function.

Market Overview

• The Spain Primary Hyperoxaluria market is projected to grow from $10M in 2025 to $22M by 2035.
• Market growth is driven by:
• Increasing adoption of RNA-targeted and disease-modifying therapies
• Improved genetic testing and earlier diagnosis
• Future growth will depend on therapies that effectively reduce oxalate production and improve long-term renal outcomes.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• Alnylam Pharmaceuticals
• YolTech Therapeutics Co., Ltd.
• Arbor Biotechnologies
• Dicerna Pharmaceuticals, Inc., a Novo Nordisk company